Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells

被引:85
|
作者
Mego, Michal [2 ,3 ,4 ]
De Giorgi, Ugo [2 ,3 ]
Dawood, Shahenaah [3 ]
Wang, Xuemei [5 ]
Valero, Vicente [3 ]
Andreopoulou, Eleni [3 ]
Handy, Beverly [3 ]
Ueno, Naoto T. [3 ]
Reuben, James M. [2 ]
Cristofanilli, Massimo [1 ]
机构
[1] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA
[2] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Morgan Welch Inflammatory Breast Canc Res Program, Dept Breast Med Oncol, Houston, TX 77030 USA
[4] Comenius Univ, Sch Med, Dept Med Oncol, Bratislava, Slovakia
[5] Comenius Univ, Sch Med, Dept Biostat, Bratislava, Slovakia
关键词
circulating tumor cells; prognostic factor; breast cancer; EPITHELIAL-MESENCHYMAL TRANSITION; PROGNOSTIC FACTORS; PERIPHERAL-BLOOD; CHEMOTHERAPY; SURVIVAL; SYSTEM;
D O I
10.1002/ijc.25690
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective study included 292 MBC patients evaluated between January 2004 and December 2007. CTC were enumerated before patients started a new line of treatment using the CellSearch (TM). Overall survival (OS) was calculated from the date of CTC measurement and estimated by the Kaplan-Meier product limit method. CTC were not detected in 35.96% patients, whereas 40.75% patients had CTC >= 5. Undetectable CTC status was positively correlated with presence of brain metastasis (OR: 6.17, 95% CI 5 2.14-17.79; p = 0.001), and inversely correlated with bone metastasis (OR: 0.47; 95% CI = 0.27-0.80; p = 0.01). In multivariate analysis, hormone receptors, number of metastatic sites and lines of therapy were independent prognostic factors for OS in patients without detectable CTC. Patients without detectable CTC before starting of a new line of therapy comprise a heterogeneous group with substantially different prognosis. We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC.
引用
收藏
页码:417 / 423
页数:7
相关论文
共 50 条
  • [31] Dysmetabolic Circulating Tumor Cells Are Prognostic in Metastatic Breast Cancer
    Brisotto, Giulia
    Biscontin, Eva
    Rossi, Elisabetta
    Bulfoni, Michela
    Piruska, Aigars
    Spazzapan, Simon
    Poggiana, Cristina
    Vidotto, Riccardo
    Steffan, Agostino
    Colombatti, Alfonso
    Huck, Wilhelm T. S.
    Cesselli, Daniela
    Zamarchi, Rita
    Turetta, Matteo
    Del Ben, Fabio
    CANCERS, 2020, 12 (04)
  • [32] Exome sequencing of circulating tumor cells in metastatic breast cancer
    Ignatiadis, M.
    Rothe, F.
    Peeters, D.
    Rouas, G.
    Smeets, D.
    Haan, J.
    Lambrechts, D.
    Campbell, P.
    Piccart, M.
    Voet, T.
    Dirix, L.
    Venet, D.
    Sotiriou, C.
    CANCER RESEARCH, 2017, 77
  • [33] Impact of apoptotic circulating tumor cells in metastatic breast cancer
    Wallwiener, M.
    Deutsch, T. M.
    Riethdorf, S.
    Hartkopf, A. D.
    Taran, F-A
    Trumpp, A.
    Brucker, S.
    Schuetz, F.
    Rom, J.
    Pantel, K.
    Schneeweiss, A.
    CANCER RESEARCH, 2016, 76
  • [34] Expression profiling of circulating tumor cells in metastatic breast cancer
    Julie E. Lang
    Janet H. Scott
    Denise M. Wolf
    Petr Novak
    Vasu Punj
    Mark Jesus M. Magbanua
    Weizhu Zhu
    Neal Mineyev
    Christopher M. Haqq
    Julia R. Crothers
    Laura J. Esserman
    Debasish Tripathy
    Laura van ’t Veer
    John W. Park
    Breast Cancer Research and Treatment, 2015, 149 : 121 - 131
  • [35] Circulating tumor cells as prognostic marker in metastatic breast cancer
    Andreopoulou, Eleni
    Cristofanilli, Massimo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2010, 10 (02) : 171 - 177
  • [36] Clinical Utility of Circulating Tumor Cells in Metastatic Breast Cancer
    Bidard, Francois-Clement
    Pierga, Jean-Yves
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (14) : 1622 - +
  • [37] Circulating tumor cells in patients with metastatic urothelial cancer
    Milowsky, M. I.
    Ishill, N. M.
    Riches, J.
    Fleisher, M.
    Trout, A.
    Valentini, A.
    Boyle, M. G.
    Bajorin, D. F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [38] Gene expression profiles of circulating tumor cells in metastatic breast cancer patients.
    Mostert, Bianca
    Sieuwerts, Anieta M.
    Kraan, Jaco
    Vries, Joan Bolt-de
    Peeters, Dieter
    Dirix, Luc
    Seynaeve, Caroline M.
    Jager, A.
    de Jongh, Felix E.
    Hamberg, Paul
    Stouthard, Jacqueline
    Kehrer, Diederik F. S.
    Look, Maxime P.
    Smid, Marcel
    Jiang, Yuqiu
    Wang, Yixin
    Gratama, Jan W.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
    Antonio Giordano
    Mario Giuliano
    Michelino De Laurentiis
    Antonio Eleuteri
    Francesco Iorio
    Roberto Tagliaferri
    Gabriel N. Hortobagyi
    Lajos Pusztai
    Sabino De Placido
    Kenneth Hess
    Massimo Cristofanilli
    James M. Reuben
    Breast Cancer Research and Treatment, 2011, 129 : 451 - 458
  • [40] Circulating tumor cells as a prognostic factor independent of obesity in metastatic breast cancer patients
    Giuliano, M.
    Giordano, A.
    Patt, A.
    Hsu, L.
    Alvarez, R. H.
    Ueno, N. T.
    Valero, V.
    Hortobagyi, G. N.
    Cristofanilli, M.
    Reuben, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)